Silence Therapeutics has spoken up about its phase 1 polycythemia vera (PV) clinical trial, providing an early look at how its siRNA prospect may match up to rivals from Incyte and Takeda.

Silence Therapeutics became the latest biotech to see its chief executive hit the exit.

Mark Rothera is leaving effective immediately, Silence announced late Monday, marking the end of his roughly 17-month tenure. In his place, the biotech elevated CFO Craig Tooman to the CEO and president roles, where he’ll attempt to shepherd a slate of early-stage and preclinical RNAi programs forward.

Silence Therapeutics has announced collaboration with Hansoh Pharmaceutical to develop new therapeutics using Silence’s mRNAi GOLD platform.

Silence Therapeutics has outlined plans to list its stock on Nasdaq, giving it access to U.S. investors to support the progress of its internal and AstraZeneca-partnered RNA therapeutics.

London-based Silence has traded on the stock exchange in its home city since the 1990s, when it was called Stanford Rook Holdings and focused on an immunotherapy treatment for tuberculosis. The modern version of Silence emerged around a decade later, after late-phase failures while called Stanford and SR Pharma led the biotech to pivot to RNA by acquiring Atugen and Intradigm.

Silence Therapeutics announces a collaboration with AstraZeneca to discover and develop siRNA therapeutics for cardiovascular, renal, metabolic, and respiratory diseases.